Complication rates after hip or knee arthroplasty in morbidly obese patients

Clinical Orthopaedics and Related Research

Volumn 471, Issue 10, 2013, Pages 3358-3366

  Friedman, Richard J ^a   Hess, Susanne ^b   Berkowitz, Scott D ^c   Homering, Martin ^b  

^a Charleston Orthopaedic Associates   (United States)

^b BAYER PHARMA AG   (Germany)

^c Bayer HealthCare Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; ASYMPTOMATIC DISEASE; BLOOD TRANSFUSION; BODY MASS; DEEP VEIN THROMBOSIS; DIARRHEA; ERYTHEMA; FEMALE; GASTROINTESTINAL PAIN; HIP ARTHROPLASTY; HUMAN; KNEE ARTHROPLASTY; LUNG EMBOLISM; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; PERIPHERAL EDEMA; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURGICAL INFECTION;

EID: 84884702549     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1007/s11999-013-3049-9     Document Type: Article

References (24)

1. Amin AK, Patton JT, Cook RE, Brenkel IJ. Does obesity influence the clinical outcome at five years following total knee replacement for osteoarthritis? J Bone Joint Surg Br. 2006;88:335-340.
2. Bordini B, Stea S, Cremonini S, Viceconti M, De Palma R, Toni A. Relationship between obesity and early failure of total knee prostheses. BMC Musculoskelet Disord. 2009;10:29.
3. Bourne R, Mukhi S, Zhu N, Keresteci M, Marin M. Role of obesity on the risk for total hip or knee arthroplasty. Clin Orthop Relat Res. 2007;465:185-188.
4. Bowditch MG, Villar RN. Do obese patients bleed more? A prospective study of blood loss at total hip replacement. Ann R Coll Surg Engl. 1999;81:198-200.
5. Chee YH, Teoh KH, Sabnis BM, Ballantyne JA, Brenkel IJ. Total hip replacement in morbidly obese patients with osteoarthritis: results of a prospectively matched study. J Bone Joint Surg Br. 2010;92:1066-1071.
6. Dowsey MM, Choong PF. Early outcomes and complications following joint arthroplasty in obese patients: a review of the published reports. ANZ J Surg. 2008;78:439-444.
7. Dowsey MM, Choong PF. Obesity is a major risk factor for prosthetic infection after primary hip arthroplasty. Clin Orthop Relat Res. 2008;466:153-158.
8. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-2775.
9. Guss D, Bhattacharyya T. Perioperative management of the obese orthopaedic patient. J Am Acad Orthop Surg. 2006;14:425-432.
10. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:31-39.
11. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;89:780-785.
12. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-2786.
13. Malinzak RA, Ritter MA, Berend ME, Meding JB, Olberding EM, Davis KE. Morbidly obese, diabetic, younger, and unilateral joint arthroplasty patients have elevated total joint arthroplasty infection rates. J Arthroplasty. 2009;24(6 suppl):84-88.
14. Mantilla CB, Horlocker TT, Schroeder DR, Berry DJ, Brown DL. Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty. Anesthesiology. 2003;99:552-560.
15. Memtsoudis SG, Besculides MC, Gaber L, Liu S, González Della Valle A. Risk factors for pulmonary embolism after hip and knee arthroplasty: a population-based study. Int Orthop. 2009;33:1739-1745.
16. Michalka PK, Khan RJ, Scaddan MC, Haebich S, Chirodian N, Wimhurst JA. The influence of obesity on early outcomes in primary hip arthroplasty. J Arthroplasty. 2012;27:391-396.
17. Moran M, Walmsley P, Gray A, Brenkel IJ. Does body mass index affect the early outcome of primary total hip arthroplasty? J Arthroplasty. 2005;20:866-869.
18. Patel VP, Walsh M, Sehgal B, Preston C, DeWal H, Di Cesare PE. Factors associated with prolonged wound drainage after primary total hip and knee arthroplasty. J Bone Joint Surg Am. 2007;89:33-38.
19. Pi-Sunyer X. The medical risks of obesity. Postgrad Med. 2009;121:21-33.
20. Pulido L, Ghanem E, Joshi A, Purtill JJ, Parvizi J. Periprosthetic joint infection: the incidence, timing, and predisposing factors. Clin Orthop Relat Res. 2008;466:1710-1715.
21. Schwarzkopf R, Thompson SL, Adwar SJ, Liublinska V, Slover JD. Postoperative complication rates in the 'super-obese' hip and knee arthroplasty population. J Arthroplasty. 2012;27:397-401.
22. Scott CE, Howie CR, Macdonald D, Biant LC. Predicting dissatisfaction following total knee replacement: a prospective study of 1217 patients. J Bone Joint Surg Br. 2010;92:1253-1258.
23. Suleiman LI, Ortega G, Ong'uti SK, Gonzalez DO, Tran DD, Onyike A, Turner PL, Fullum TM. Does BMI affect perioperative complications following total knee and hip arthroplasty? J Surg Res. 2012;174:7-11.
24. Turpie AGG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373:1673-1680.